Quick Search:       Advanced Search
Evaluation of long-term protective efficacy of neonatal immunoprophylaxis in children whose mothers have hepatitis B virus
Received:June 20, 2021  Revised:August 24, 2021  Click here to download the full text
Citation of this paper:XU Chen-yu,CHEN Ting-mei,HUANG Hong-yu,WANG Qin,HU Ya-li,ZHOU Yi-hua.Evaluation of long-term protective efficacy of neonatal immunoprophylaxis in children whose mothers have hepatitis B virus[J].Chinese Journal of Clinical Medicine,2021,28(5):833-837
Hits: 995
Download times: 272
Author NameAffiliationE-mail
XU Chen-yu Department of Obstetrics and Gynecology, Zhenjiang Maternal and Child Health Hospital, Zhenjiang 212001, Jiangsu, China  
CHEN Ting-mei Department of Obstetrics and Gynecology, Zhenjiang Maternal and Child Health Hospital, Zhenjiang 212001, Jiangsu, China  
HUANG Hong-yu Laboratory of Hepatitis, Nanjing Drum Tower Hospital Affiliated to Nanjing University Medical School, Nanjing 210008, Jiangsu, China  
WANG Qin Department of Obstetrics and Gynecology, Zhenjiang Maternal and Child Health Hospital, Zhenjiang 212001, Jiangsu, China  
HU Ya-li Department of Obstetrics and Gynecology, Nanjing Drum Tower Hospital Affiliated to Nanjing University Medical School, Nanjing 210008, Jiangsu, China  
ZHOU Yi-hua Laboratory of Hepatitis, Nanjing Drum Tower Hospital Affiliated to Nanjing University Medical School, Nanjing 210008, Jiangsu, China zgr03summer@126.com 
Abstract:Objective: To explore the long-term protective efficacy of neonatal immunoprophylaxis in children whose mothers have hepatitis B virus (HBV). Methods: A cohort of 246 children whose mothers have hepatitis B and hepatitis B surface antigen (HBsAg) negative from November 2011 and March 2012. They were scheduled to have a second follow-up from January to May 2017. The data of hepatitis B revaccination and hepatitis history during two follow-ups were recorded, and blood samples were collected for the hepatitis B markers examination. Results: A total of 197 (80.1%) children, with a mean age of (8.9±1.4) years, participated in the follow-up. All children were HBsAg negative, and 99 (50.3%) children were anti-HBs positive (≥ 10 mU/mL). during the two follow-ups, 31 children were revaccinated with the hepatitis B vaccine. Among these children, the median anti-HBs level increased from 10.7 to 98.4 mU/mL (P<0.05), and the anti-HBs positive rate increased from 51.6% to 93.5% (P<0.05). Among 166 children who did not receive revaccination, the median anti-HBs level dropped from 41.7 to 7.3 mU/mL (P<0.05), anti-HBs became negative in 67 children, and the positive rate of anti-HBs decreased from 77.7% to 42.2% (P<0.05). Of 37 children, with anti-HBs <10 mU/mL at the first follow-up, 28 (75.7%) still had anti-HBs <10 mU/mL. In addition, 30 (18.1%) of the 166 un-revaccinated children showed increased anti-HBs levels, but no one was anti-HBc positive. Conclusions: After neonatal immunoprophylaxis, anti-HBs level in children of HBsAg-positive mothers was declined with the growing age and most unrevaccinated children had anti-HBs <10 mU/mL, but none of them was infected with HBV. These results indicate that neonatal immunoprophylaxis has long-term protection against HBV and revaccination is not required.
keywords:hepatitis B virus  mother  offspring  immunoprophylaxis  antibody to hepatitis B surface antigen  long-term protection
HTML  View Full Text  View/Add Comment  Download reader